Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse

  • Kemppainen, S.
  • Aramburu-Núñez, M.
  • Koivisto, H.
  • Posado-Fernández, A.
  • Felix-Garcia, M. R.
  • Nurminen, K.
  • Häkli, S.
  • Abelli-Deulofeu, E.
  • Kaisto, M.
  • Custodia, A.
  • van Olst, L.
  • Willman, R-M
  • Mäkinen, P.
  • Miettinen, P. O.
  • Schouten, M.
  • Iglesias-Rey, Ramón
  • Kamermans, A.
  • Martiskainen, H.
  • Rauramaa, T.
  • de Vries, H. E.
  • Eng, E.
  • Salo, R.
  • Kettunen, M.
  • Gröhn, O.
  • Gureviciene, I.
  • Chmielevski, P.
  • Ouro, A.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • Doria, G.
  • Flores, O.
  • Aguiar, P.
  • Carmans, S.
  • Roucourt, B.
  • Hiltunen, M.
  • Sobrino, T.
  • Tanila, H.
Pathological tau accumulation disrupts neuronal function, leading to neurodegeneration and dementia in tauopathies, such as Alzheimer's disease and frontotemporal dementia. Despite the progression of several anti-tau therapies to clinical trials, no disease-modifying treatments for tauopathies exist. Tau hyperphosphorylation is a key factor in pathology progression. Among all tau phosphorylation sites targeted in preclinical passive immunization studies, the classic AT8 pathological tau phosphorylation sites have remained understudied. Thus, we investigated the potential of immunotherapy against phosphorylated tau (pTau) in a P301S mouse model of tauopathy. We administered a new monoclonal B6 antibody that targets tau phosphorylation sites at serine 202, threonine 205 and serine 208 either systemically for 3 months or locally into the cerebral ventricles for 1 or 2 months via an osmotic minipump. Systemic administration failed to reach the brain effectively, and subsequently, was not able to alleviate the progressive motor impairment seen in this tauopathy mouse model. By contrast, intraventricular administration improved motor function in earlier stages of pathology but had a lesser effect in later stages. The local administration for 8 weeks reduced the number of pTau positive neurons in cortex and hippocampus. Our findings indicate that targeting the classical pathological tau phosphorylation sites can ameliorate tau pathology and improve function in a mouse tauopathy model. These results add to growing evidence supporting the efforts in developing tau-targeting immunotherapies for neurodegenerative diseases associated with pathological tau deposits., This research was funded by the European Union, Horizon 2020 project PANA, grant number 686009, Academy of Finland (grant numbers 338182, 307866, 315459, and 330178, 339767); the Sigrid Jusélius Foundation (SJ-2022) and the Strategic Neuroscience Funding of the University of Eastern Finland (NEURO-RC-2019). A.P-F.'s grant was funded by the European Union's FP7 Marie-Curie Initial Training Network program (grant agreement 606950). This study was also funded by grants from the Xunta de Galicia (IN607A2022/07), Instituto de Salud Carlos III (ISCIII) (PI22/00938, PI21/00727, CIBERNED CB22/05/00067, and RD21/0006/0005) and Ministerio de Ciencia e Innovación (RTC2019-007373-1 and PDC2022-134000-I00). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018_NEUROATLANTIC project), INTER-REG V A España Portugal (POCTEP) (0624_2IQBIONEURO_6_E), and the European Regional Development Fund (ERDF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed